Page last updated: 2024-08-24

ranolazine and bisoprolol

ranolazine has been researched along with bisoprolol in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Al-Lamee, R; Davies, JR; Foley, M; Francis, DP; Ganesananthan, S; Gerber, R; Howard, J; Keeble, TR; Malik, IS; Nijjer, S; Nowbar, AN; O'Kane, P; Petraco, R; Rajkumar, CA; Seligman, H; Sen, S; Sharp, ASP; Shun-Shin, M; Tang, KH	1

Reviews

1 review(s) available for ranolazine and bisoprolol

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for ranolazine and bisoprolol

Article	Year
Achieving Optimal Medical Therapy: Insights From the ORBITA Trial. Journal of the American Heart Association, 2021, 02-02, Volume: 10, Issue:3 Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isosorbide Dinitrate; Male; Middle Aged; Nicorandil; Percutaneous Coronary Intervention; Ranolazine; Treatment Outcome; Vasodilator Agents	2021

Article

Year

Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.

Journal of the American Heart Association, 2021, 02-02, Volume: 10, Issue:3

Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isosorbide Dinitrate; Male; Middle Aged; Nicorandil; Percutaneous Coronary Intervention; Ranolazine; Treatment Outcome; Vasodilator Agents

2021